M&A deals, company strategies, pipeline updates and more
Follow our coverage of the 2019 J.P. Morgan Healthcare Conference in San Francisco
A connection between TDP-43, which has been implicated in ALS, and another gene could yield new approaches to treating the disease.
Verily has received a 510(k) clearance from the FDA for its own clinical study smartwatch, complete with an on-demand ECG.
In this paper, we discuss some of the risks associated with the supply chain as well as the characteristics of a technology solution that can help you mitigate…
Telehealth equipment maker Tyto Care raised an extra $9 million through its series C round, bringing its total up to $33.5 million.
Abbott has exercised a three-year-old option to purchase Cephea Valve Technologies, a developer of mitral heart valve replacements.
CMO Sean Bohen and I-O head David Berman are leaving AstraZeneca, while Roche's Omar Khwaja and Pearl Huang land at new biotechs.
Celgene ended the week by expanding its CAR-T toolkit via a deal with Obsidian and placing an $80 million bet on Kyn.
A few days after leaving Insmed to take up an “employment opportunity on the West Coast”, Paul Streck has popped up at migraine specialist Alder.
The collaboration will analyze MRI data from 35,000 multiple sclerosis patients and results from IL-17 inhibitor trials.
Apple and J&J are teaming up to see if the Apple Watch can help catch and diagnose seniors with atrial fibrillation earlier and faster than before.
A University of Chicago teams has shown that a derivative of the hypertension drug Wytensin can protect myelin in animal models of multiple sclerosis.